Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2024

Open Access 01-12-2024 | Lupus Nephritis | Research article

Long noncoding RNAs (CTC-471J1.2, NeST) as epigenetic risk factors of active juvenile lupus nephritis: a case-control study

Authors: Mohamed M. Zedan, Ali Sobh, Alshimaa Magdy, Mai S. Korkor, Zeinab R. Attia, Nada Khaled, Yousra Sadeq, Ahmed Hazem El-Nagdy, Ahmed E. Taha, Mohamed Ahmed Noureldin, Mohamed Taman, Doaa Mosad Mosa, Marwa H. Elnagdy

Published in: Pediatric Rheumatology | Issue 1/2024

Login to get access

Abstract

Background

Measurement of the circulating levels of long-non-coding RNAs (lncRNAs) in lupus nephritis (LN) patients could dramatically explore more insights about the disease pathogenesis. Hence, we aimed to quantify the level of expression of CTC-471J1.2 and NeST in LN patients and to correlate it with the disease activity.

Method

This case-control study was conducted on a group of children with juvenile LN attending to Mansoura University Children’s Hospital (MUCH). Demographics, clinical, and laboratory findings were collected besides the measurement of lncRNAs by quantitative real-time PCR.

Results

The expression level of lncRNAs-CTC-471J1.2 was significantly down-regulated in children with active LN versus inactive cases or controls. In contrast, the NeST was significantly up-regulated in active LN cases. A significant correlation was found between CTC-471J1.2 expression and LN activity parameters. Additionally, both lncRNAs showed a reasonable sensitivity and specificity in differentiation of active LN. A regression analysis model revealed that CTC-471J1.2 and NeST were independent predictors of active nephritis.

Conclusion

The expression level of circulatory lncRNAs-CTC-471J1.2 and NeST can be used as sensitive and specific biomarkers for active LN. Furthermore, both could serve as predictors for nephritis activity.
Literature
1.
2.
Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174–94.CrossRefPubMed
3.
La Paglia GMC, Leone MC, Lepri G, Vagelli R, Valentini E, Alunno A, et al. One year in review 2017: systemic lupus erythematosus. Clin Exp Rheumatol. 2017;35(4):551–61.PubMed
4.
Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun. 2010;34(2):121–6.CrossRefPubMed
5.
6.
Zuo Y, Xu H. Involvement of long noncoding RNAs in the pathogenesis of autoimmune diseases. J Transl Autoimmun. 2020;3:100044.CrossRef
7.
8.
Cao HY, Li D, Wang YP, Lu HX, Sun J, Li HB. Clinical significance of reduced expression of lncRNA TUG1 in the peripheral blood of systemic lupus erythematosus patients. Int J Rheum Dis. 2020;23(3):428–34.CrossRefPubMed
9.
Saleh A, Kasem HE, Zahran E, El-Hefnawy SM. Dysregulation of cell-free long non-coding RNAs (NEAT2, CTC-471J1.2 and lnc-DC) in Egyptian systemic lupus and lupus nephritis patients. Meta Gene. 2020;24:100665.CrossRef
10.
Gomez JA, Wapinski OL, Yang YW, Bureau JF, Gopinath S, Monack DM, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743–54.CrossRefPubMedPubMedCentral
11.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.CrossRefPubMed
12.
Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
13.
Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.PubMed
14.
Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002;46(2):436–44.CrossRefPubMed
15.
Mosca M, Merrill JT, Bombardieri S. Chapter 2 - assessment of disease activity in systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS, editors. Systemic lupus erythematosus. Philadelphia: Mosby; 2007. p. 19–23.CrossRef
16.
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–30.CrossRefPubMed
17.
Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983;75(3):382–91.CrossRefPubMed
18.
Wu GC, Li J, Leng RX, Li XP, Li XM, Wang DG, et al. Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. Oncotarget. 2017;8(14):23650–63.CrossRefPubMedPubMedCentral
19.
Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274.CrossRefPubMed
20.
Yougbaré I, Boire G, Roy M, Lugnier C, Rouseau E. NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production. Can J Physiol Pharmacol. 2013;91(5):353–61.CrossRefPubMed
21.
Liu Q, Zhang X, Dai L, Hu X, Zhu J, Li L, et al. Long noncoding RNA related to cartilage injury promotes chondrocyte extracellular matrix degradation in osteoarthritis. Arthritis Rheumatol. 2014;66(4):969–78.CrossRefPubMed
22.
Wu Y, Zhang F, Ma J, Zhang X, Wu L, Qu B, et al. Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):131.CrossRefPubMedPubMedCentral
23.
Zhang F, Wu L, Qian J, Qu B, Xia S, La T, et al. Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. J Autoimmun. 2016;75:96–104.CrossRefPubMed
24.
Luo Q, Li X, Xu C, Zeng L, Ye J, Guo Y, et al. Integrative analysis of long non-coding RNAs and messenger RNA expression profiles in systemic lupus erythematosus. Mol Med Rep. 2018;17(3):3489–96.PubMed
25.
Mihaylova G, Vasilev V, Kosturkova MB, Stoyanov GS, Radanova M. Long non-coding RNAs as new biomarkers in lupus nephritis: a connection between present and future. Cureus. 2020;12(7):e9003.PubMedPubMedCentral
26.
Masutani K, Taniguchi M, Nakashima H, Yotsueda H, Kudoh Y, Tsuruya K, et al. Upregulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy. Nephrol Dial Transplant. 2004;19(3):580–6.CrossRefPubMed
27.
28.
Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, et al. The long noncoding RNA THRIL regulates TNF alpha expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A. 2014;111(3):1002–7.CrossRefPubMed
29.
30.
Gao Y, Li S, Zhang Z, Yu X, Zheng J. The role of long non-coding RNAs in the pathogenesis of RA, SLE, and SS. Front Med (Lausanne). 2018;5:193.CrossRefPubMed
Metadata
Title
Long noncoding RNAs (CTC-471J1.2, NeST) as epigenetic risk factors of active juvenile lupus nephritis: a case-control study
Authors
Mohamed M. Zedan
Ali Sobh
Alshimaa Magdy
Mai S. Korkor
Zeinab R. Attia
Nada Khaled
Yousra Sadeq
Ahmed Hazem El-Nagdy
Ahmed E. Taha
Mohamed Ahmed Noureldin
Mohamed Taman
Doaa Mosad Mosa
Marwa H. Elnagdy
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2024
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-023-00945-1

Other articles of this Issue 1/2024

Pediatric Rheumatology 1/2024 Go to the issue

Research article

Bone health and physical activity in adolescents with juvenile idiopathic arthritis: a cross-sectional case-control study

Letter to the Editor

Algorithmic approach in the diagnosis of pediatric uveitis

Research article

Body mass index is associated with health-related quality of life and disease characteristics in young adults with juvenile idiopathic arthritis

Case Report

Rheumatological complaints in H syndrome: from inflammatory profiling to target treatment in a case study

Case Report

Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review

Research article

Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial